These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 20023661)
1. The activating receptor NKp46 is essential for the development of type 1 diabetes. Gur C; Porgador A; Elboim M; Gazit R; Mizrahi S; Stern-Ginossar N; Achdout H; Ghadially H; Dor Y; Nir T; Doviner V; Hershkovitz O; Mendelson M; Naparstek Y; Mandelboim O Nat Immunol; 2010 Feb; 11(2):121-8. PubMed ID: 20023661 [TBL] [Abstract][Full Text] [Related]
2. Recognition and killing of human and murine pancreatic beta cells by the NK receptor NKp46. Gur C; Enk J; Kassem SA; Suissa Y; Magenheim J; Stolovich-Rain M; Nir T; Achdout H; Glaser B; Shapiro J; Naparstek Y; Porgador A; Dor Y; Mandelboim O J Immunol; 2011 Sep; 187(6):3096-103. PubMed ID: 21849674 [TBL] [Abstract][Full Text] [Related]
3. The expression of the beta cell-derived autoimmune ligand for the killer receptor nkp46 is attenuated in type 2 diabetes. Gur C; Enk J; Weitman E; Bachar E; Suissa Y; Cohen G; Schyr RB; Sabanay H; Horwitz E; Glaser B; Dor Y; Pribluda A; Hanna JH; Leibowitz G; Mandelboim O PLoS One; 2013; 8(8):e74033. PubMed ID: 24009765 [TBL] [Abstract][Full Text] [Related]
4. Targeting natural killer cell reactivity by employing antibody to NKp46: implications for type 1 diabetes. Yossef R; Gur C; Shemesh A; Guttman O; Hadad U; Nedvetzki S; Miletić A; Nalbandyan K; Cerwenka A; Jonjic S; Mandelboim O; Porgador A PLoS One; 2015; 10(2):e0118936. PubMed ID: 25719382 [TBL] [Abstract][Full Text] [Related]
5. Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. Glasner A; Ghadially H; Gur C; Stanietsky N; Tsukerman P; Enk J; Mandelboim O J Immunol; 2012 Mar; 188(6):2509-15. PubMed ID: 22308311 [TBL] [Abstract][Full Text] [Related]
6. The natural cytotoxicity receptor NKp46 is dispensable for IL-22-mediated innate intestinal immune defense against Citrobacter rodentium. Satoh-Takayama N; Dumoutier L; Lesjean-Pottier S; Ribeiro VS; Mandelboim O; Renauld JC; Vosshenrich CA; Di Santo JP J Immunol; 2009 Nov; 183(10):6579-87. PubMed ID: 19846871 [TBL] [Abstract][Full Text] [Related]
7. Human anti-NKp46 antibody for studies of NKp46-dependent NK cell function and its applications for type 1 diabetes and cancer research. Berhani O; Glasner A; Kahlon S; Duev-Cohen A; Yamin R; Horwitz E; Enk J; Moshel O; Varvak A; Porgador A; Jonjic S; Mandelboim O Eur J Immunol; 2019 Feb; 49(2):228-241. PubMed ID: 30536875 [TBL] [Abstract][Full Text] [Related]
8. Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. Halfteck GG; Elboim M; Gur C; Achdout H; Ghadially H; Mandelboim O J Immunol; 2009 Feb; 182(4):2221-30. PubMed ID: 19201876 [TBL] [Abstract][Full Text] [Related]
9. Increased NK cell immunity in a transgenic mouse model of NKp46 overexpression. Glasner A; Isaacson B; Viukov S; Neuman T; Friedman N; Mandelboim M; Sexl V; Hanna JH; Mandelboim O Sci Rep; 2017 Oct; 7(1):13090. PubMed ID: 29026144 [TBL] [Abstract][Full Text] [Related]
10. The Murine Natural Cytotoxic Receptor NKp46/NCR1 Controls TRAIL Protein Expression in NK Cells and ILC1s. Sheppard S; Schuster IS; Andoniou CE; Cocita C; Adejumo T; Kung SKP; Sun JC; Degli-Esposti MA; Guerra N Cell Rep; 2018 Mar; 22(13):3385-3392. PubMed ID: 29590608 [TBL] [Abstract][Full Text] [Related]
11. Tumor immunoediting by NKp46. Elboim M; Gazit R; Gur C; Ghadially H; Betser-Cohen G; Mandelboim O J Immunol; 2010 May; 184(10):5637-44. PubMed ID: 20404273 [TBL] [Abstract][Full Text] [Related]
12. NK cell development in bone marrow and liver: site matters. Gotthardt D; Prchal-Murphy M; Seillet C; Glasner A; Mandelboim O; Carotta S; Sexl V; Putz EM Genes Immun; 2014 Dec; 15(8):584-7. PubMed ID: 25319498 [TBL] [Abstract][Full Text] [Related]
13. NKp46 Recognizes the Sigma1 Protein of Reovirus: Implications for Reovirus-Based Cancer Therapy. Bar-On Y; Charpak-Amikam Y; Glasner A; Isaacson B; Duev-Cohen A; Tsukerman P; Varvak A; Mandelboim M; Mandelboim O J Virol; 2017 Oct; 91(19):. PubMed ID: 28724773 [TBL] [Abstract][Full Text] [Related]
14. Dependence of innate lymphoid cell 1 development on NKp46. Wang Y; Dong W; Zhang Y; Caligiuri MA; Yu J PLoS Biol; 2018 Apr; 16(4):e2004867. PubMed ID: 29702643 [TBL] [Abstract][Full Text] [Related]
15. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Satoh-Takayama N; Vosshenrich CA; Lesjean-Pottier S; Sawa S; Lochner M; Rattis F; Mention JJ; Thiam K; Cerf-Bensussan N; Mandelboim O; Eberl G; Di Santo JP Immunity; 2008 Dec; 29(6):958-70. PubMed ID: 19084435 [TBL] [Abstract][Full Text] [Related]
16. Conditional ablation of NKp46+ cells using a novel Ncr1(greenCre) mouse strain: NK cells are essential for protection against pulmonary B16 metastases. Merzoug LB; Marie S; Satoh-Takayama N; Lesjean S; Albanesi M; Luche H; Fehling HJ; Di Santo JP; Vosshenrich CA Eur J Immunol; 2014 Nov; 44(11):3380-91. PubMed ID: 25142413 [TBL] [Abstract][Full Text] [Related]